| Date Filed | Type | Description |
| 03/25/2021 |
GN
| Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights |
| 03/01/2021 |
GN
| Satsuma Pharmaceuticals Announces Updated STS101 Development Plan |
| 11/24/2020 |
GN
| Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference |
| 11/02/2020 |
GN
| Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences |
| 09/03/2020 |
GN
| Satsuma Pharmaceuticals to Participate in September Virtual Investor Conferences |
| 08/12/2020 |
GN
| Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results |
| 07/07/2020 |
GN
| Satsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of Directors |
| 06/11/2020 |
GN
| Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society's Annual Scientific Meeting Hosted via a Virtual Meeting Platform |
| 06/01/2020 |
GN
| Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine |
| 05/27/2020 |
GN
| Satsuma Pharmaceuticals to To Present at the Jefferies Virtual Healthcare Conference |
| 05/18/2020 |
GN
| Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform |
| 05/12/2020 |
GN
| Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results |
| 03/10/2020 |
GN
| Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results |
| 03/05/2020 |
GN
| Satsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial Officer |
| 02/18/2020 |
GN
| Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference |
| 01/28/2020 |
GN
| Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain |
| 11/26/2019 |
GN
| Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference |
| 11/12/2019 |
GN
| Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results |
| 04/23/2014 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 04/22/2014 |
4
| EISENHART WILLIAM L (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/ |
| 04/22/2014 |
4
| BEHAR HOWARD (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/ |
| 04/22/2014 |
4
| BILLER LESLIE S (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/|
Txns:
| Disposed/sold 530,304 shares
@ $0
Disposed/sold 141,044 options to buy
@ $21.47, valued at
$3M
|
|
| 04/22/2014 |
4
| BOGGS PAULA (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/ |
| 04/22/2014 |
4
| BOYER ELLEN RM (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/|
Txns:
| Disposed/sold 7,134 shares
@ $0
Disposed/sold 2,626 options to buy
@ $21.76, valued at
$57.1k
|
|
| 04/22/2014 |
4
| BUTTERFIELD ROBERT G (Controller/Prin. Acct. Officer) has filed a Form 4 on STERLING FINANCIAL CORP /WA/ |
| 04/22/2014 |
4
| EDWARDS WEBB (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/|
Txns:
| Disposed/sold 6,981 shares
@ $0
Disposed/sold 2,626 options to buy
@ $21.76, valued at
$57.1k
|
|
| 04/22/2014 |
4
| POPE MARIA M (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/|
Txns:
| Disposed/sold 1,169 shares
@ $0
Disposed/sold 1,817 options to buy
@ $26.04, valued at
$47.3k
|
|
| 04/22/2014 |
4
| Hartheimer Robert Herman (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/ |
| 04/22/2014 |
4
| DONEGAN BOB C (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/|
Txns:
| Disposed/sold 8,013 shares
@ $0
Disposed/sold 2,626 options to buy
@ $21.76, valued at
$57.1k
Disposed/sold 31 options to buy
@ $2189.22, valued at
$67.9k
|
|
| 04/22/2014 |
4
| Reuling Michael F (Director) has filed a Form 4 on STERLING FINANCIAL CORP /WA/ |
| 04/22/2014 |
4
| RUSNAK PATRICK J (CFO) has filed a Form 4 on STERLING FINANCIAL CORP /WA/|
Txns:
| Disposed/sold 14,232 shares
@ $0
Disposed/sold 14 shares
@ $0
Disposed/sold 1,151 shares
@ $0
Disposed/sold 7,005 options to buy
@ $21.76, valued at
$152.4k
Disposed/sold 7,352 restricted stock units
@ $0
Disposed/sold 2,810 restricted stock units
@ $0 |
|
| 04/22/2014 |
4
| HAUSCHILD STEVEN D (Chief Credit Officer) has filed a Form 4 on STERLING FINANCIAL CORP /WA/ |
| 04/22/2014 |
4
| Eckhardt Ezra (COO - Sterling Financial Corp.) has filed a Form 4 on STERLING FINANCIAL CORP /WA/|
Txns:
| Disposed/sold 74,046 shares
@ $0
Disposed/sold 13,340 shares
@ $0
Disposed/sold 925 shares
@ $0
Disposed/sold 1,468 shares
@ $0
Disposed/sold 8,231 options to buy
@ $21.76, valued at
$179.1k
Disposed/sold 3,746 restricted stock units
@ $0
Disposed/sold 8,639 restricted stock units
@ $0
Disposed/sold 13,469 restricted stock units
@ $0
Disposed/sold 9,771 restricted stock units
@ $0 |
|
| 04/22/2014 |
4
| SCHULTHEIS ANDREW J (General Counsel) has filed a Form 4 on STERLING FINANCIAL CORP /WA/ |
|